Advertisement
Nanobiotix S.A. (NBTX)
NASDAQ: NBTX
· Real-Time Price · USD
3.24
0.04 (1.25%)
At close: Apr 29, 2025, 10:02 AM
1.25% (1D)
| Bid | 3.2 |
| Market Cap | 152.64M |
| Revenue (ttm) | 42.2M |
| Net Income (ttm) | -33.47M |
| EPS (ttm) | -1.63 |
| PE Ratio (ttm) | -1.99 |
| Forward PE | -7.63 |
| Analyst | Buy |
| Ask | 3.56 |
| Volume | 1,325 |
| Avg. Volume (20D) | 10,309 |
| Open | 3.21 |
| Previous Close | 3.20 |
| Day's Range | 3.21 - 3.27 |
| 52-Week Range | 2.76 - 7.51 |
| Beta | 1.55 |
About NBTX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 108
Stock Exchange NASDAQ
Ticker Symbol NBTX
Website https://www.nanobiotix.com
Advertisement
Analyst Forecast
According to 1 analyst ratings, the average rating for NBTX stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 146.91% from the latest price.
Stock Forecasts1 month ago
+18.51%
Nanbotix shares are trading higher after the compa...
Unlock content with
Pro Subscription
3 months ago
+7.26%
Nanobiotix shares are trading higher after the company announced it began its Phase 2 trial for an innovative cancer treatment in stage 3 lung cancer.
